Bayer’s cancer treatment Stivarga has been granted priority review status by the FDA for use as a second line treatment of unresectable hepatocellular carcinoma (uHCC).
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
